Form 4 for ABCL AbCellera Biologics Inc.
Accepted 2023-02-23 00:00:00 ET · period of report 2023-02-22 · accession 0001209191-23-012199 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-23 | 2023-02-22 | ABCL | Hansen Carl L. G. | CEO, Dir, 10% | M - OptEx | $2.70 | +56.1K | 505.1K | +12% | +$151.5K |
| D | 2023-02-23 | 2023-02-22 | ABCL | Hansen Carl L. G. | CEO, Dir, 10% | M - OptEx | $0.00 | -56.1K | 6.56M | -0.8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2023-02-22 | M | A | 56,125 | $2.70 | 505,125 | D | — | — | |
| 2 | Derivative | Share option (right to buy) | 2023-02-22 | M | D | 56,125 | $0.00 | 6,557,566 | D | $2.70 · — to 2030-11-18 | 56,125 Common Shares | (F2) The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. |